Erlotinib Plus Ramucirumab: Ready for Prime Time? By Narjust Duma, MD, and Gilberto Lopes, MD, MBA, FAMS, FASCODecember 10, 2019 The treatment of epidermal growth factor receptor (EGFR)-positive lung cancer changed dramatically after the results of the FLAURA trial showed improved progression-free survival with…
The U.S. Food and Drug Administration (FDA) approved atezolizumab and hyaluronidase-tqjs (Tecentriq Hybreza) for subcutaneous injection for all the adult indications as the intravenous formulation…
In a systematic analysis of global literature, researchers estimated the proportion of invasive cervical cancer cases caused by specific HPV genotypes.
Researchers have explored whether an artificial intelligence (AI)-based tool could help to detect immune-related adverse events in patients with cancer.
In patients with early-stage triple-negative breast cancer, the addition of atezolizumab to standard adjuvant chemotherapy provided no benefit over chemotherapy alone in the final analysis…
In a meta-analysis reported in JAMA Oncology, Nielsen and colleagues estimated the risk of cardiotoxicity associated with immune checkpoint inhibitor (ICI) treatment of cancers.
Imagine walking into a fancy restaurant only to find a menu consisting mostly of kids’ dishes. It would make no sense. Just 25% of restaurant…
In a meta-analysis reported in JAMA Oncology, Villacampa et al explored the impact on outcomes of adding neoadjuvant immune checkpoint inhibitor therapy to chemotherapy among…
The phase III CAPItello-291 trial compared health-related quality of life (HRQOL) outcomes with capivasertib/fulvestrant vs placebo/fulvestrant in patients with previously treated hormone receptor–pos…
Despite significant improvements in the perception of biomarker testing, substantial barriers to implementation may persist globally, according to findings presented at the International Association f…
Researchers may have uncovered a metabolic pathway that could lead to the development of predictive biomarkers for immune checkpoint inhibitors in NSCLC, according to findings…
